21 min listen
Realizing the Promise of IL-2 Therapies with AI
FromThe Bio Report
ratings:
Length:
23 minutes
Released:
Dec 13, 2023
Format:
Podcast episode
Description
Interleukin-2 therapies have been seen as promising ways to treat solid tumors, but they have proven challenging because of the ability of IL-2 to both activate and suppress the immune system. Their effectiveness has been limited because of potentially toxic side effects, which have included vascular leak syndrome and pulmonary edema. Aulos Biosciences believes the AI-based approach to computational drug design used for its lead experimental therapy allows it to unlock the power of IL-2 without triggering the concerning side effects of existing therapies. We spoke to Aron Knickerbocker, president and CEO of Aulos Biosciences, about the potential for IL-2 therapies to treat solid tumors, the limits of todays IL-2 therapies, and the AI-based design behind its experimental IL-2 therapy in development.
Released:
Dec 13, 2023
Format:
Podcast episode
Titles in the series (100)
Reengineering Drug Discovery and Development: Drugmakers have employed new technologies to reduce the cost and time and it takes develop drugs and produce therapies that more precisely target the underlying biology driving diseases. Boston-based Berg Pharma is using artificial intelligence with ... by The Bio Report